Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles

Biomaterials

Volumn 35, Issue 5, 2014, Pages 1696-1704

  Lee, Hong Jai ^a   Park, Hee Ho ^a   Kim, Jeong Ah ^b   Park, Ju Hyun ^a   Ryu, Jina ^a   Choi, Jeongseon ^a   Lee, Jongmin ^a   Rhee, Won Jong ^c   Park, Tai Hyun ^a,d  

^a Seoul National University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c SolarLight Ltd   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Drug delivery; Drug release; Enzyme stability; Protein; Protein nanoparticle

Indexed keywords

CELL CULTURE MEDIA; DRUG RELEASE; ENZYME STABILITY; HUMAN SERUM ALBUMINS; INTRACELLULAR STABILITY; PHOSPHATE-BUFFERED SALINES; PROTEIN NANOPARTICLES; THERAPEUTIC PROTEIN;

BIODEGRADATION; CELL CULTURE; DRUG DELIVERY; DYES; ENZYMES; PROTEINS; RECOMBINANT PROTEINS; STABILITY;

NANOPARTICLES;

BETA GALACTOSIDE; CELL ENZYME; HUMAN SERUM ALBUMIN; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; RECOMBINANT 30KC19 PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CULTURE MEDIUM; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME STABILITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALIA; BOMBYX MORI;

DRUG DELIVERY; DRUG RELEASE; ENZYME STABILITY; PROTEIN; PROTEIN NANOPARTICLE;

BETA-GALACTOSIDASE; DRUG CARRIERS; HEK293 CELLS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; RECOMBINANT PROTEINS; SERUM ALBUMIN;

EID: 84890155567     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.001     Document Type: Article

References (31)

1. Cho K., Wang X., Nie S., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14(5):1310-1316.
2. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263(5153):1600-1603.
3. Wang A.Z., Gu F., Zhang L., Chan J.M., Radovic-Moreno A., Shaikh M.R., et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 2008, 8(8):1063-1070.
4. Kumar M. Nano and microparticles as controlled drug delivery devices. JPharm Pharm Sci 2000, 3(2):234-258.
5. Langer K., Balthasar S., Vogel V., Dinauer N., Von Briesen H., Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003, 257(1):169-180.
6. Kommareddy S., Amiji M. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug Chem 2005, 16(6):1423-1432.
7. Irache J., Merodio M., Arnedo A., Camapanero M., Mirshahi M., Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem 2005, 5(3):293-305.
8. Weber C., Coester C., Kreuter J., Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 2000, 194(1):91-102.
9. Azarmi S., Tao X., Chen H., Wang Z., Finlay W.H., Löbenberg R., et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006, 319(1):155-161.
10. Rhee W.J., Park T.H. Silkworm hemolymph inhibits baculovirus-induced insect cell apoptosis. Biochem Biophys Res Commun 2000, 271(1):186-190.
11. Choi S.S., Rhee W.J., Kim E.J., Park T.H. Enhancement of recombinant protein production in Chinese hamster ovary cells through anti-apoptosis engineering using 30Kc6 gene. Biotechnol Bioeng 2006, 95(3):459-467.
12. Rhee W.J., Kim E.J., Park T.H. Kinetic effect of silkworm hemolymph on the delayed host cell death in an insect cell-baculovirus system. Biotechnol Prog 1999, 15(6):1028-1032.
13. Choi S.S., Rhee W.J., Park T.H. Beneficial effect of silkworm hemolymph on a CHO cell system: inhibition of apoptosis and increase of EPO production. Biotechnol Bioeng 2005, 91(7):793-800.
14. Rhee W.J., Kim E.J., Park T.H. Silkworm hemolymph as a potent inhibitor of apoptosis in Sf9 cells. Biochem Biophys Res Commun 2002, 295(4):779-783.
15. Kim E.J., Park H.J., Park T.H. Inhibition of apoptosis by recombinant 30K protein originating from silkworm hemolymph. Biochem Biophys Res Commun 2003, 308(3):523-528.
16. Ha S., Park T. Efficient production of recombinant protein in Spodoptera frugiperda/AcNPV system utilizing silkworm hemolymph. Biotechnol Lett 1997, 19(11):1087-1091.
17. Ha S.H., Park T.H., Kim S.-E. Silkworm hemolymph as a substitute for fetal bovine serum in insect cell culture. Biotechnol Tech 1996, 10(6):401-406.
18. Kim E.J., Rhee W.J., Park T.H. Inhibition of apoptosis by a Bombyx mori gene. Biotechnol Prog 2004, 20(1):324-329.
19. Park J.H., Wang Z., Jeong H.-J., Park H.H., Kim B.-G., Tan W.-S., et al. Enhancement of recombinant human EPO production and glycosylation in serum-free suspension culture of CHO cells through expression and supplementation of 30Kc19. Appl Microbiol Biotechnol 2012, 96(3):671-683.
20. Wang Z., Park J.H., Park H.H., Tan W., Park T.H. Enhancement of recombinant human EPO production and sialylation in Chinese hamster ovary cells through Bombyx mori 30Kc19 gene expression. Biotechnol Bioeng 2011, 108(7):1634-1642.
21. Park J.H., Lee J.H., Park H.H., Rhee W.J., Choi S.S., Park T.H. Aprotein delivery system using 30Kc19 cell-penetrating protein originating from silkworm. Biomaterials 2012, 33(35):9127-9134.
22. von Storp B., Engel A., Boeker A., Ploeger M., Langer K. Albumin nanoparticles with predictable size by desolvation procedure. JMicroencapsul 2012, 29(2):138-146.
23. Zensi A., Begley D., Pontikis C., Legros C., Mihoreanu L., Wagner S., et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. JControl Release 2009, 137(1):78-86.
24. Park J.H., Park H.H., Choi S.S., Park T.H. Stabilization of enzymes by the recombinant 30Kc19 protein. Process Biochem 2012, 47(1):164-169.
25. Langer K., Anhorn M., Steinhauser I., Dreis S., Celebi D., Schrickel N., et al. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 2008, 347(1):109-117.
26. Elzoghby A.O., Samy W.M., Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. JControl Release 2012, 157(2):168-182.
27. Harush-Frenkel O., Rozentur E., Benita S., Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 2008, 9(2):435-443.
28. Schnitzer J. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol Heart Circ Physiol 1992, 262(1):246-254.
29. Rybin V.O., Xu X., Lisanti M.P., Steinberg S.F. Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae: a mechanism to functionally regulate the camp signaling pathway. JBiol Chem 2000, 275(52):41447-41457.
30. Wang L., Connelly M.A., Ostermeyer A.G., Chen H.-H., Williams D.L., Brown D.A. Caveolin-1 does not affect SR-BI-mediated cholesterol efflux or selective uptake of cholesteryl ester in two cell lines. JLipid Res 2003, 44(4):807-815.
31. Yang J.-P., Ma X.-X., He Y.-X., Li W.-F., Kang Y., Bao R., et al. Crystal structure of the 30K protein from the silkworm Bombyx mori reveals a new member of the β-trefoil superfamily. JStruct Biol 2011, 175(1):97-103.